© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cancer medicine has changed a lot over the past few decades. Irinotecan Hydrochloride Trihydrate comes from a long line of thinking that started back in the 1960s, with researchers poking at camptothecin, a natural compound from the Camptotheca acuminata tree. In earlier days, folks noticed the tree had properties that slowed down cancer cells. That pure camptothecin turned out to be a bit too rough for people, but around the late 1980s and early 1990s, Japanese researchers isolated and modified the basic structure, landing on irinotecan. After it moved out of trial stages, the FDA approved it for cancer treatment in 1996. The road to the now widely used tri-hydrate form involved improving the compound's ability to dissolve in water and dial down some tricky side effects, making it easier to produce, ship and store in hospitals across the world.
Irinotecan Hydrochloride Trihydrate stands out among cancer chemotherapy drugs, especially for folks facing colorectal and lung cancers. Its structure builds off the base camptothecin, tweaked and stabilized, then capped with a hydrochloride and three water molecules in the crystalline form. Used in both research settings and clinics, it forms the backbone of several popular chemotherapy regimens, like FOLFIRI, teaming up with other agents to combat cancer's stubborn cells more effectively. I've seen hospital pharmacies bust open bottles with its off-white powder inside, prepping personalized doses for patients week in and week out. Demand stays steady; its position in modern oncology never really fades.
Look at a batch of irinotecan hydrochloride trihydrate and you’ll see a pale yellow powder. Chemically, it wears the formula C33H38N4O6•HCl•3H2O and maps out at a molecular weight just over 677 daltons. It dissolves well in water, which always makes things simpler for preparing infusions. The compound’s melting point hovers around 230°C (with decomposition), and that steady structure keeps it stable enough for both long-term storage and shipment across continents. Often, impurities or breakdown come from excessive heat and humidity, so care gets taken throughout the supply chain. This careful attention to its physical details means patients get the real-deal compound, dose after dose.
Vials and packaging come packed with information, a testament to how seriously manufacturers and regulators take patient safety. The product label outlines identity (as irinotecan hydrochloride trihydrate), potency, pH value (usually about 3.5 after reconstitution), and directions for dilution before intravenous use. Traceability sits front and center, with each vial carrying batch numbers, expiry dates, and manufacturer details. Hospitals keep these records up to date, ever-mindful of the risks that come with mixing up drugs in busy chemotherapy suites. The specification standards, like those spelled out in the United States Pharmacopeia or the European Pharmacopoeia, make sure hospitals everywhere dispense the same product every time. Each lot undergoes quality control: purity not less than 98%, identification by IR and HPLC, and precise moisture content, all to catch any hiccups before these vials land in patient care.
There’s something both intricate and deliberate about synthesizing irinotecan hydrochloride trihydrate. Starting from camptothecin, the raw material goes through a series of carefully planned reaction steps that modernize the classic structure. Synthetic chemists attach a piperidino side chain at position 10 using a Mannich reaction—a tricky bit, requiring controlled pH and well-regulated temperature. Once the base irinotecan forms, introducing hydrochloric acid invites the salt to take shape, and the final step hydrates the entire complex with purified water under controlled atmospheric conditions. Each part of this process deals with sensitive, high-value reagents, meaning error margins must stay tight and batch-to-batch reproducibility matters immensely. These realities define the industrial life of this cancer drug.
The chemistry around irinotecan didn’t just stop after its initial launch. Scientists still poke and prod at the molecule to try to improve its performance and lower toxicity. Take the famous conversion to its active metabolite, SN-38, which actually delivers the real punch against tumor cells; that change happens inside the liver, where carboxylesterase enzymes snip off a group and fire up its true activity. In labs, researchers explore side-chain tweaks, like altering the piperidino group or shielding reactive oxygen positions, aiming for longer circulation times or reduced gastrointestinal toxicity. Some labs experiment with nanoparticles and liposome encapsulation to help drugs home in on tumors while sparing healthy tissue. The story of irinotecan’s chemistry reads like an ongoing tug-of-war between cancer cell resilience and molecular ingenuity.
Folks working in hospital pharmacies, research labs, or even regulatory offices know irinotecan hydrochloride trihydrate by a few names. Its chemical identity spells out as ((4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl)[1,4′-bipiperidin]-1′-yl-, hydrochloride, trihydrate. Commercially, the most popular brand rides under Camptosar (in the United States), but elsewhere it wears badges like CPT-11 or Onivyde (for liposomal irinotecan). Pharmacologists sometimes refer to it as SN-38 precursor, since the metabolite brings the action in cell-killing. Different markets and formulators stamp their own labels, but the drug inside stays the same workhorse molecule.
No one can ignore how powerful—yet dangerous—anticancer drugs like irinotecan hydrochloride trihydrate can be. Pharmacies and hospital wards use strict protocols to keep both patients and staff safe. Personal protective equipment covers everyone handling the powder, and preparation usually takes place inside negative-pressure hoods built to filter hazardous dust and vapors. Sharps disposal, spill kits, and rigorous documentation all help keep the margin for error low. Staff must train regularly on safe handling, because irinotecan can cause severe eye and mucous membrane irritation, and some folks have allergic reactions. Major organizations like the Occupational Safety and Health Administration (OSHA), as well as the National Institute for Occupational Safety and Health (NIOSH), have outlined clear rules. Unused powder or leftover solution never makes its way into regular waste: incineration handles it all, leaving the public’s water supply and soil safe.
Doctors reach for irinotecan hydrochloride trihydrate mainly for patients with colon and rectal cancer, especially in advanced cases when first-line therapy starts to lose its punch. It's also proven useful in certain lung cancers, pediatric tumors, and even rare gynecological cancers. Some practitioners run it solo, but more often it teams up with 5-fluorouracil and leucovorin in the FOLFIRI regimen, or with oxaliplatin for tougher cases. Oncologists use genetic screening to guess who might respond best, paying special attention to people with mutations in their UGT1A1 gene, as these patients face higher risks for certain side effects. Some researchers and pharmaceutical companies keep digging into other cancers and delivery combos, hoping to crack tough cases where standard lines have failed.
The 21st century has seen a push to reimagine irinotecan. Academic labs and drug developers have gone after ways to improve its selectivity and shrink the laundry list of side effects. Nanoparticle delivery systems, antibody-drug conjugates, and combination therapies with immune checkpoint inhibitors are all in play. The underlying goal: chase more cancer cell kill with less harm to healthy tissue. Some clinical trials examine ways to optimize dosing schedules or predict who will metabolize the drug most safely. Basic research still unfolds in animal models, testing new analogues in hopes of finding one version that's even better. Regulatory agencies watch closely, clearing the way for innovations only after safety and real clinical benefit shine through the data.
Every patient, nurse, and pharmacist knows irinotecan packs a wallop not only against cancer but sometimes the patient, too. Toxicity research stretches all the way back to animal studies before approval, but post-marketing studies still surface new challenges. Diarrhea—both early (cholinergic) and late (secretory)—remains one of the top dose-limiting nightmares. Some patients run high fevers, catch infections, and struggle with low blood cell counts, all of which can land someone in the hospital. Preclinical studies mapped out damage potential for the gut lining and liver, and ongoing clinical studies keep tying side effects back to genetic differences, especially the UGT1A1*28 allele. Tracking pharmacogenetic links between metabolism, dosing, and side effect profiles stands as a crucial part of day-to-day practice. Hospitals walk a fine line, balancing life-saving effects with a side effect profile that commands respect.
Irinotecan hydrochloride trihydrate faces a future brimming with both challenge and promise. Advances in delivery—like liposomal formulations and conjugation with antibodies—hold real hope for cutting down on side effects and boosting tumor-shrinking capacity. Personalized medicine keeps pushing to the front of the pack, with efforts focusing on tailoring doses to genetic make-up or using liquid biopsies to time administration for maximum impact. Basic science keeps chipping away at mechanisms of resistance, looking for clever molecular tweaks that will outmaneuver the cancer cell’s uncanny ability to adapt. As generic versions flood the market, access rises, but the real prize lies with making the treatment ever safer, smarter, and more effective. Those of us who see the toll cancer takes and the hope new therapies give can’t help but push for a future where precision trumps side effects, where a week in chemotherapy brings more benefit and less heartbreak. That’s the goal shared across labs, clinics, and cancer wards the world over.
Walking into an oncology center always feels a little heavy. You see people fighting for some hope, waiting for news, or holding onto courage. Among the many vials and pills on those shelves, irinotecan hydrochloride trihydrate stands as a power tool used in the fight against cancer, especially tough cases of colorectal cancer. Doctors reach for this drug when surgery or basic chemotherapy doesn’t hold the line. You hear names like “Camptosar” tossed around, but behind those names sits real science working to slow the spread of cancer cells that could otherwise keep marching through the body unchecked.
Irinotecan blocks certain enzymes that cancer cells need to copy themselves—one in particular called topoisomerase I. By jamming up the cell’s copy machine, it forces many of these fast-growing cells to die off before they can multiply. That’s the kind of news you want in a field where every bit of progress buys a patient more time and options, especially if their cancer has spread to other organs.
You might meet someone getting irinotecan as part of a standard combo—often mixed with other big names like fluorouracil and leucovorin—to create an offense known as FOLFIRI. Studies have shown that adding irinotecan to the fight can push survival for colorectal cancer patients months further, and sometimes longer, especially when treatment starts early enough. Every extra month matters to a patient who wants to see a graduation, meet a grandchild, or just get one more holiday dinner with family.
There’s no sugar-coating some of the side effects that come with this drug. People receiving irinotecan often face diarrhea so severe that it sends them back to the hospital. Others deal with low white blood cell counts, which makes small infections a big worry. Nausea, tiredness, and hair loss can hit hard. Each appointment comes with questions for the care team about how to dial back the impact without reducing the punch this drug packs against cancer.
Doctors and nurses pay careful attention to these risks. Pharmacists and oncologists work together to set up regimens—antidiarrheal medicine, careful blood tests, extra fluids—so someone can stay strong enough for what’s next. There’s a balancing act: push the treatment hard enough to stall cancer growth, but pull back quick if side effects become life-threatening. Each patient’s journey calls for a hands-on approach, backed up by guidelines built from decades of research and honest feedback from patients who’ve already walked the path.
Some research teams are searching for new ways to use irinotecan, or to combine it with other treatments like immunotherapy or targeted drugs. There’s always hope on the horizon as clinical trials test whether tweaks to dosing or new combinations can keep cancer in check longer, while easing up on the symptoms that turn daily life upside down. One day, patients might look back and see irinotecan as an important bridge—something that helped pave the road to even better treatments in the future.
Irinotecan Hydrochloride Trihydrate steps in as a chemotherapy medicine. Doctors prescribe it for cancers like colon and rectal cancer. It helps slow cancer down, but brings along a list of side effects that can turn everyday life upside down. My years watching a loved one take this drug taught me that knowing what’s likely to happen helps families brace themselves. It gives patients and caregivers a fighting chance to handle the physical and emotional swings cancer treatment can bring.
Stomach trouble shows up first for many. Diarrhea can become severe—sometimes right after an infusion, other times days later. There’s immediate diarrhea, which calls for careful monitoring right in the clinic. Delayed diarrhea pops up after a few days, sometimes lasting longer than anyone would like. This isn’t just uncomfortable; losing fluids can push someone into dehydration fast. It’s something care teams see a lot, which is why doctors often send people home with loperamide (Imodium) right from the get-go. My friend drank oral rehydration solutions between chemo cycles just to keep his strength up.
Fatigue hits everyone a little differently, but almost nobody escapes it. You feel exhausted, and sleep doesn’t bring much relief. Irinotecan thins out white blood cells, red blood cells, and platelets. That means easier bruising and a higher risk of getting infections. Some people need hospital time for low counts or fever. Nurses pay close attention to these lab results. Doctors sometimes reduce doses or space out treatments if blood counts dip too low.
Hair loss feels like a small thing to anyone not going through it. But for the person in treatment, seeing hair fall out in clumps can be a tough reminder of the battle happening inside. Irinotecan causes thinning or complete loss of scalp hair in a lot of people—sometimes eyebrows and lashes go too. Scarves and hats help, but it’s more about finding support and sharing experiences with others who "get it."
Mouth sores—doctors call them mucositis—are common. The mouth feels raw and eating anything spicy or crunchy becomes a struggle. Soft foods and cold drinks helped my friend get by. Some clinics recommend rinsing with salt water or prescribed mouthwashes. These little steps keep daily nutrition on track.
Nausea and vomiting still tag along with chemo. Anti-nausea medications before and after infusions make things easier for many. Keeping something bland on hand and eating in small amounts works for others. Knowing the pattern helps—if nausea comes on day one, you learn to prep ahead of time.
Chemotherapy drugs like irinotecan aren’t gentle. They take a toll. No surprise, then, that patients and caregivers want more than a list—they need real solutions. Early communication makes a difference. Doctors can tailor supportive medicines, hydration, and nutrition tips to the person, not just the diagnosis. Encouraging patients to call about diarrhea, fevers, or mouth changes right away saves lives. Support groups and counseling help too. Patients handle even tough side effects a little better if they know what’s coming and they don’t feel alone in it.
Doctors pick chemotherapy treatments with care. Irinotecan Hydrochloride Trihydrate stands out for several types of cancer, especially colon and rectal cancers. Nurses give this medicine through a drip, straight into the bloodstream, usually at a hospital or cancer center. The infusion isn’t rushed—patients sit for anywhere from thirty minutes to ninety minutes as the medicine enters the body.
I’ve seen family members go through this process. The slow pace helps reduce side effects. Nurses monitor every detail: making sure the vein stays healthy, listening for early warning signs like dizziness or trouble breathing. Everyone in the room pays close attention, since irinotecan can hit hard, with side effects that need quick action.
Most chemotherapy drugs get broken down too quickly if taken by mouth. With intravenous administration, the medicine moves right into the blood, bypassing the digestive system. That means a steadier, more predictable action in fighting cancer cells. In a study published by the National Cancer Institute, direct infusion showed higher effectiveness for colorectal cancer than any oral preparation or off-label approach. My own observations bear this out—patients tend to show stronger tumor response and better chances of shrinking cancer when the schedule gets followed.
The schedule involves detailed math. Oncologists calculate the dose based on body surface area, lab results, and how the patient did with past treatments. These calculations aren’t just routine. The difference of just a few milligrams can tip the scales between manageable nausea and severe problems.
Cancer drugs come with a price. Irinotecan, in particular, brings on diarrhea, low white blood counts, and hair loss. The effects can feel overwhelming. I remember talking with a man in his sixties who got so dehydrated after one round he needed a hospital stay just to recover. That’s why monitoring during and after the drip makes a real difference.
Before each cycle, nurses do blood work to check for infection risk. During treatment, patients get anti-nausea drugs and instructions for home care. The staff teaches families how to handle sudden diarrhea or fever. If something looks off, doctors can change the protocol on the fly—maybe slow the infusion, push fluids, or delay the next round.
Support teams step in. Even in modern hospitals, patients feel scared and isolated, hearing the beeps from infusion pumps and seeing other patients in similar chairs. Social workers, nutritionists, and cancer navigators share tips: drink more fluids, eat light meals, tell your nurse about new symptoms. These resources fill the gaps the medicine leaves behind.
Researchers keep improving the protocols. Genomic screening now sometimes guides whether irinotecan suits a patient, lowering risks and boosting the odds of a good response. In my own circle, a friend’s dose adjustment based on his genetic test meant fewer side effects, and he finished therapy on schedule.
Effective cancer care goes beyond the chemical itself. The way irinotecan gets administered—paced slowly and monitored closely—shows that small details can save lives. Keeping communication open among patients, families, and healthcare providers helps find trouble early and adapt fast. Each step makes a tough process just a bit more human.
Irinotecan Hydrochloride Trihydrate handles cancer with real force, especially colon and rectal cancers that have spread. The benefits save lives, but anyone starting treatment should look at the risks closely. Irinotecan is not just another medicine. It’s strong, and the body tells the story. Severe diarrhea knocks on the door for many patients. Not just any run-of-the-mill stomach trouble — this can land people in the hospital if ignored. Some folks get hit just a few hours after their first dose; others face it days later. I’ve seen someone end up weaker than they started, not from the cancer, but from dehydration and salt loss brought on by the drug. If anyone begins this treatment, stock up on fluids, alert the doctor if dehydration starts, and learn the signs: dizziness, dry mouth, sunken eyes.
Every doctor or pharmacist will talk about the blood counts. Irinotecan can wipe out the white blood cells. Infection strikes easily when the immune system goes down. As a caregiver at a chemotherapy center, I’ve watched patients with an ordinary scratch wind up with a fever and a quick trip to the ER. Fevers above 38˚C after chemo need fast action, not a wait-and-see approach. Never ignore chills or a sore throat. A weekly checkup for complete blood counts keeps surprises away.
Some medicines quietly sneak up on the liver. Irinotecan can be one of those. Folks with liver problems already should let their oncologist know. Liver tests at regular intervals show if the medicine is causing trouble early enough for a doctor to take action. Less common but still possible, this drug can cause lung problems, such as cough and shortness of breath. Anybody noticing new chest pain should call their team without delay.
One thing that doesn’t get enough attention is how much genetics play a role in this drug’s effects. An enzyme called UGT1A1, which helps clear irinotecan, varies a lot from person to person. Some people break down the medicine slowly because of their genes and face more powerful side effects. It makes sense for doctors to test for this enzyme, especially if the patient is from a group with higher chances of poor metabolizers. This test isn’t just science — it can prevent serious problems for real people.
Salty snacks and sports drinks might seem out of place at a chemotherapy center, but they’ve saved a few of my patients from a tough hospital stay. People at home need clear instructions about timing medication for diarrhea. Loperamide at the first sign, not hours later. Keep a fever thermometer handy, and write down all medicines, including over-the-counter and supplements, for every visit. Some drugs like St. John’s Wort can make irinotecan less effective, so full honesty about everything being taken matters. There’s no need to face all this alone — bringing a notebook and a friend or family member along to appointments helps keep track of the details.
Open communication fixes problems that paperwork can’t. Every patient has a right to ask questions until everything makes sense. My experience tells me that small misunderstandings — like waiting too long to report diarrhea, or skipping a blood test — lead to big setbacks. The best outcomes come from teams who talk, listen, and respond quickly. Irinotecan Hydrochloride Trihydrate doesn’t act alone, and neither should patients.
Cancer rarely plays fair. Doctors have spent decades fighting it from every angle. Irinotecan Hydrochloride Trihydrate is a chemotherapy medicine often used for colon and rectal cancer. Its job: stop cancer cells from multiplying. What really stands out is how this drug often works alongside others instead of alone.
Real progress tends to happen when treatments join forces. The most common mix? Irinotecan teams up with fluorouracil and leucovorin. This trio, sometimes called FOLFIRI, has saved lives and bought precious time. I remember talking to an oncologist who explained how patients sometimes respond better to combinations, especially if the cancer has already learned a few tricks from single drugs.
Cancer cells change fast. One medicine can slow them down for a while, but pretty soon, cancer can find ways to grow again. Doctors use different types of drugs together to attack the problem from several angles. A cancer cell might dodge one bullet, but a well-planned combo often hits harder. Studies from the National Cancer Institute back this up, showing that pairing irinotecan with other chemo medicines has led to longer survival in colorectal cancer.
Mixing drugs, though, isn’t as simple as putting everything in a blender. Each medicine has its own risks. More drugs can mean more side effects, like diarrhea or low white blood cells, making infections a real threat. That’s something nobody should gloss over. Real people deal with these problems every day, sometimes for months on end.
Lately, research has gone beyond the old standards. Now, doctors sometimes add targeted therapies such as bevacizumab (Avastin) or cetuximab. These treatments work differently from old-fashioned chemo. They zero in on cancer’s weak spots, like faulty growth signals, which sometimes boosts results when paired with irinotecan.
One of my neighbors joined a clinical trial pairing FOLFIRI with a checkpoint inhibitor, a type of immunotherapy. The experience was rough. She had days when she could barely eat, but the tumor shrank more than it did with FOLFIRI alone. It’s not always a smooth process, though. Combining treatments piles on more side effects, and not every patient tolerates it. But stories like hers highlight why combinations draw so much interest.
There’s no single recipe for success. Oncologists tailor combinations based on each patient: age, general health, genetic quirks in the tumor, and previous side effects. That’s especially true with irinotecan, which can be toxic for some people, depending on their metabolism.
Genetic tests now help pick the best approach. Some folks break down irinotecan slower than others, which increases the risk of serious side effects. Labs can catch this before treatment starts. Tools like this keep people safer while giving them a shot at better results.
There’s no doubt—combining irinotecan with other cancer treatments changes lives. The challenge is finding the best mix for each person. More clinical trials can point the way, especially for rare cancers or tough cases. Doctors and researchers also need to keep listening to patients about what feels manageable in daily life—not just which results look best on a chart.
Nobody fighting cancer wants one-size-fits-all medicine solutions. Progress comes down to science, strong partnerships between doctors and patients, and a willingness to adapt. Irinotecan—by itself and especially in combinations—gives patients options, and that matters each step of the way.
| Names | |
| Preferred IUPAC name | (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidin-1-ylpiperidin-1-yl)carbonyl]oxy-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride trihydrate |
| Other names |
Camptosar CPT-11 irinotecan hydrochloride irinotecan irinotecan HCl trihydrate |
| Pronunciation | /ˌaɪ.rɪ.noʊˈtiː.kæn haɪˌdrɒk.ləˌraɪd traɪˈhaɪˌdreɪt/ |
| Identifiers | |
| CAS Number | 136572-09-3 |
| Beilstein Reference | 62742 |
| ChEBI | CHEBI:8707 |
| ChEMBL | CHEMBL1252 |
| ChemSpider | 28744599 |
| DrugBank | DB00762 |
| ECHA InfoCard | 03e211f6-1c55-43b2-98ff-199a6b175b16 |
| EC Number | 602-119-0 |
| Gmelin Reference | 882229 |
| KEGG | D04544 |
| MeSH | D000077358 |
| PubChem CID | 607717 |
| RTECS number | GV7875000 |
| UNII | EV4Y44Q48J |
| UN number | UN3466 |
| Properties | |
| Chemical formula | C33H38N4O6·HCl·3H2O |
| Molar mass | 677.19 g/mol |
| Appearance | White to yellowish crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Soluble in water |
| log P | 2.67 |
| Acidity (pKa) | pKa = 8.1 |
| Basicity (pKb) | 8.05 |
| Magnetic susceptibility (χ) | -8.6×10^-6 cm³/mol |
| Refractive index (nD) | 1.56 |
| Viscosity | Viscous liquid |
| Dipole moment | 6.75 D |
| Pharmacology | |
| ATC code | L01XX19 |
| Hazards | |
| Main hazards | May cause cancer; may damage fertility or the unborn child; causes serious eye irritation; may cause respiratory irritation. |
| GHS labelling | GHS02, GHS06, GHS08 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H351, H360, H373 |
| Precautionary statements | P201, P202, P261, P264, P270, P272, P280, P281, P302+P352, P304+P340, P305+P351+P338, P308+P313, P332+P313, P333+P313, P337+P313, P362+P364, P405, P501 |
| NFPA 704 (fire diamond) | 1-2-2-0 |
| Lethal dose or concentration | LD50 (Mouse, IV): 158 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse: 218 mg/kg (IV) |
| NIOSH | NS613G96RC |
| PEL (Permissible) | Not established |
| REL (Recommended) | 60 mg/m² |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Camptothecin Topotecan SN-38 Irinotecan |
